Bio-Path Holdings, Inc. (NASDAQ:BPTH) Sees Large Decline in Short Interest

Bio-Path Holdings, Inc. (NASDAQ:BPTH) was the recipient of a significant decline in short interest in the month of November. As of November 15th, there was short interest totalling 38,100 shares, a decline of 51.0% from the October 31st total of 77,800 shares. Based on an average daily volume of 1,160,000 shares, the days-to-cover ratio is currently 0.0 days. Approximately 0.9% of the company’s shares are short sold.

Wall Street Analyst Weigh In

Separately, StockNews.com initiated coverage on shares of Bio-Path in a report on Sunday. They issued a “sell” rating on the stock.

Bio-Path Trading Down 4.3 %

Shares of NASDAQ:BPTH traded down $0.03 during midday trading on Thursday, reaching $0.77. 61,635 shares of the company were exchanged, compared to its average volume of 1,102,472. Bio-Path has a fifty-two week low of $0.61 and a fifty-two week high of $12.37. The stock has a fifty day simple moving average of $0.95 and a two-hundred day simple moving average of $1.47.

Institutional Trading of Bio-Path

An institutional investor recently bought a new position in Bio-Path stock. Armistice Capital LLC bought a new stake in Bio-Path Holdings, Inc. (NASDAQ:BPTH) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 97,000 shares of the company’s stock, valued at approximately $194,000. Armistice Capital LLC owned approximately 4.66% of Bio-Path as of its most recent filing with the Securities and Exchange Commission. 5.74% of the stock is currently owned by institutional investors and hedge funds.

About Bio-Path

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.